Meeting
2018 Genitourinary Cancers Symposium
Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
Authors
Rosa Maria Nadal
National Institutes of Health, Bethesda, MD
Rosa Maria Nadal , Amir Mortazavi , Mark Stein , Sumanta K. Pal , Nicole N. Davarpanah , Howard L. Parnes , Yang-Min Ning , Lisa M. Cordes , Mohammadhadi H. Bagheri , Liza Lindenberg , Ryan Thompson , Seth M. Steinberg , Tina Moore , Tiffany Lancaster , Milisyaris Velez , Esther Mena , Rene Costello , Donald Bottaro , William L. Dahut , Andrea B. Apolo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT02496208
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 515)
DOI
10.1200/JCO.2018.36.6_suppl.515
Abstract #
515
Poster Bd #
K22
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).
First Author: Scot Anthony Niglio
Poster
2018 ASCO Annual Meeting
Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).
First Author: Rosa Nadal
Poster
2017 Genitourinary Cancers Symposium
A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.
First Author: Andrea B. Apolo
Poster
2017 ASCO Annual Meeting
A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
First Author: Andrea B. Apolo